|
Entacapone (INN) is a medication commonly used in combination with other medications for the treatment of Parkinson's disease. Entacapone together with levodopa and carbidopa allows levodopa to have a longer effect in the brain and reduces Parkinson’s disease signs and symptoms for a greater length of time than levodopa and carbidopa therapy alone.〔 Entacapone is known as a selective and reversible inhibitor of the catechol-O-methyltransferase (COMT) enzyme.〔 When taken together with levodopa (L-DOPA) and carbidopa, entacapone stops the catechol-O-methyltransferase enzyme from breaking down and metabolizing levodopa, resulting in an overall increase of levodopa remaining in the brain and body.〔 Entacapone is developed by Orion Pharma and marketed by Novartis under the trade name Comtan.〔 Stalevo, another medication developed by Orion Pharma and marketed by Novartis, is a single tablet formulation that contains levodopa, carbidopa, and entacapone. == Medical use == Entacapone is used in addition to levodopa and carbidopa for people with Parkinson's disease to treat the signs and symptoms of end-of-dose "wearing-off."〔 "Wearing-off" is characterized by the re-appearance of both motor and non-motor symptoms of Parkinson’s disease occurring towards the end of a previous levodopa and carbidopa dose. In clinical trials, entacapone has not been shown to slow progression or reverse Parkinson’s disease.〔〔〔 Entacapone is an orally active drug that can be taken with or without food. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Entacapone」の詳細全文を読む スポンサード リンク
|